Centerpulse settles opt-outs
This article was originally published in The Gray Sheet
Executive Summary
Swiss company reaches settlements Nov. 6 with 16 individuals who opted out of a $725 mil. hip-and-knee class action settlement and had revision surgery. The firm must still resolve suits with 43 non-revision patients. On Nov. 4, Centerpulse transferred $725 mil. to a settlement trust in Cleveland, completing its obligations to class participants. Funds were raised through a capital increase via a tradeable preemptive rights offering, in addition to bank credit (1"The Gray Sheet" Sept. 23, 2002, p. 17)...
You may also be interested in...
Financings In Brief
LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.